GSK (LON:GSK) Earns Hold Rating from Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating reiterated by investment analysts at Deutsche Bank Aktiengesellschaft in a note issued to investors on Tuesday, Digital Look reports. They presently have a GBX 2,000 price target on the stock. Deutsche Bank Aktiengesellschaft’s target price would indicate a potential upside of 7.61% from the stock’s previous close.

Several other analysts also recently issued reports on GSK. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 1,975 price target on shares of GSK in a report on Tuesday, September 8th. Berenberg Bank boosted their price target on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a research note on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, GSK presently has an average rating of “Hold” and an average price target of GBX 2,064.38.

GSK Stock Performance

LON GSK opened at GBX 1,858.50 on Tuesday. The business has a fifty day moving average of GBX 1,899.20 and a 200-day moving average of GBX 1,964.02. GSK has a fifty-two week low of GBX 1,455 and a fifty-two week high of GBX 2,282. The stock has a market cap of £74.47 billion, a price-to-earnings ratio of 15.78, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 103.36.

GSK (LON:GSK) last issued its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Buying and Selling at GSK

In other news, insider Jeannie Lee acquired 802 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of GBX 5,069 per share, with a total value of £40,653.38. Also, insider Vishal Sikka acquired 1,266 shares of GSK stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average cost of GBX 5,069 per share, with a total value of £64,173.54. In the last three months, insiders acquired 3,625 shares of company stock valued at $13,494,563. 0.20% of the stock is owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.